

Amended Appendix 3B

PERTH, Australia and SAN FRANCISCO, California – 15 March 2024

PYC Therapeutics Limited (ASX:PYC) advises of the following amendments to the Appendix 3B lodged yesterday with the ASX¹:

Monday, 25 March 2024 – Settlement date for New Shares issued under the Institutional Entitlement Offer

Tuesday, 26 March 2024 – Issue date for New Shares issued under the Institutional Entitlement Offer & commencement of trading of such securities on the ASX

The above amendments have been made to accommodate the settlement of New Shares for shareholders participating in the Institutional Entitlement Offer.

Please refer to the ASX announcement 14 March 2024 for further information on the Entitlement Offer.

Indicative Timetable*

Event	Timing (AWST)
Trading halt	Thursday, 14 March 2024
Announcement of Entitlement Offer	Thursday, 14 March 2024
Institutional Entitlement Offer opens	Thursday, 14 March 2024
Institutional Entitlement Offer closes	4.00pm (AWST) Friday, 15 March 2024
Announcement of results of Institutional Entitlement Offer Trading halt lifted, existing securities commence trading	Monday 18 March 2024

¹ Defined terms in this announcement have the meaning prescribed in the announcement of the equity raising (see ASX announcement 'PYC Equity Raising to Raise up to \$74.6million' lodged with the ASX on 14 March 2024)

Record Date for Entitlement Offer	4.00pm (AWST) on Monday, 18 March 2024
Retail Entitlement Offer Opens (Retail Offer Booklet sent)	Wednesday, 20 March 2024
Settlement of New Shares under Institutional Entitlement Offer	Monday, 25 March 2024
Quotation of New Shares issued under the Institutional Entitlement Offer and commencement of trading of such securities on the ASX	Tuesday, 26 March 2024
Last day to extend retail offer close date (if required)	Wednesday, 3 April 2024
Retail Entitlement Offer Closes	Monday, 8 April 2024
Announcement of results of Retail Entitlement Offer	Wednesday, 10 April 2024
Allotment and issue of New Shares under Retail Entitlement Offer	Monday, 15 April 2024
New Shares under Retail Entitlement Offer commence trading on ASX	Tuesday, 16 April 2024
Holding statements sent for New Shares issued under the Retail Entitlement Offer	Wednesday, 17 April 2024

*The timetable above is indicative only and subject to change. The Company reserves the right to alter the dates above in its full discretion and without prior notice, subject to the ASX Listing Rules and the Corporations Act.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**².

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials. The Company is progressing a second blinding eye disease (Autosomal Dominant Optic Atrophy) and a third program targeting Polycystic Kidney Disease which are anticipated to commence human trials in mid-2024 and late 2024 respectively.

² Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA

info@pyctx.com